01/02/2023at 07:38

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

by christian bundgaard, translated by daniel pedersen

Novo Nordisk has a habit of playing it safe when it comes to its expectations for the fiscal year ahead.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Bank expects strong 2022 conclusion from Novo Nordisk
For subscribers
JPMorgan: Novo Nordisk to accelerate growth this year
For subscribers
Analyst: Wegovy prescriptions continue upward trend in US
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Photo: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025.

For subscribers

Pharma & biotech

Bavarian Nordic confirms 2023 outlook

The Danish vaccine maker now restates its expectations for this year that were announced earlier this month.

For subscribers

Novo Nordisk predicts wide range for 2023 sales growth

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Bank expects strong 2022 conclusion from Novo Nordisk

JPMorgan: Novo Nordisk to accelerate growth this year

Analyst: Wegovy prescriptions continue upward trend in US

Sign up for our newsletter

Front page now

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Further reading

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Bavarian Nordic confirms 2023 outlook

Jobs